Breaking News

New Jersey Innovation Institute Sells BioCentriq Subsidiary for $73M

BioCentriq manufactures autologous and allogeneic cell therapies and gene therapies and specializes in viral vector production.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

The New Jersey Innovation Institute (NJII) sold its subsidiary, BioCentriq Inc., to GC corp. for $73 million. BioCentriq manufactures autologous and allogeneic cell therapies and gene therapies and specializes in viral vector production, cell and viral banking, and upstream and downstream processing.   BioCentriq was launched in 2019 by NJII, a New Jersey Institute of Technology (NJIT) corporation that was created in 2014 to serve as a portal for higher education/industry partnerships. NJII br...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters